Penalver, F., Marquez, J., Duran, S., Giraldo, P., Martin, A., Montalban, C., . . . Cooperati, G. S. L. (2019). Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial.
Citación estilo ChicagoPenalver, FJ, et al. Response-adapted Treatment With Rituximab, Bendamustine, Mitoxantrone, and Dexamethasone Followed By Rituximab Maintenance in Patients With Relapsed or Refractory Follicular Lymphoma After First-line Immunochemotherapy: Results of the RBMDGELTAMO08 Phase II Trial. 2019.
Cita MLAPenalver, FJ, et al. Response-adapted Treatment With Rituximab, Bendamustine, Mitoxantrone, and Dexamethasone Followed By Rituximab Maintenance in Patients With Relapsed or Refractory Follicular Lymphoma After First-line Immunochemotherapy: Results of the RBMDGELTAMO08 Phase II Trial. 2019.